Company Profile
Intensity Therapeutics Stock Price, News & Analysis
- Ticker:
- INTS
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- Headquartered in the United States and listed on NASDAQ, Intensity Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Stock performance
4.00 USD (+1.65%)
Close
Last updated: June 23, 2026 at 00:00
10.81M USD
Market cap
Why the stock is moving
INTS is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Intensity Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Intensity Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Intensity Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Intensity Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Future catalysts
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
Source: Intensity Therapeutics
- 02
Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Source: Intensity Therapeutics
- 03
Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
Source: Intensity Therapeutics
- 04
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
Source: Intensity Therapeutics
- 05
Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
Source: Intensity Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Intensity Therapeutics (INTS)?
Intensity Therapeutics (INTS) most recently closed at 4.00 USD, a +1.65% move versus the previous session.
What is the market cap of Intensity Therapeutics (INTS)?
Intensity Therapeutics currently has a market capitalization of 10.81M USD on BioPharmSignal.
What does Intensity Therapeutics do?
Intensity Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
On which exchange is INTS stock listed?
Intensity Therapeutics (INTS) is associated with NASDAQ, Headquartered in the United States and listed on NASDAQ, Intensity Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts., Biotechnology.
What is Intensity?
Intensity Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Which conditions is Intensity Therapeutics targeting with Intensity?
Intensity Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
What is Therapeutics?
Intensity Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.